Diffusion Pharmaceuticals Inc. — 2019 Form 10-K
Issuer note: The request identifies Cervomed Inc., but the supplied filing is for Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN). The filing covers the fiscal year ended December 31, 2019; it is not a standalone fourth-quarter report.
Business context and reporting period
Diffusion is a clinical-stage biotechnology company with no approved products or product sales. Its lead candidate, trans sodium crocetinate (TSC), is being developed to improve oxygen diffusion in hypoxic tissue. The principal programs are a Phase 2 pre-hospital stroke trial and a Phase 3 glioblastoma (GBM) trial whose randomized portion had not begun. RES-529, an oncology and ophthalmology candidate, is also in the portfolio.
Financial performance and position
| Metric | 2019 | 2018 |
|---|---|---|
| Product revenue | None | None |
| Research and development expense | $6.62 million | $5.75 million |
| General and administrative expense | $4.83 million | $6.17 million |
| Operating loss | $11.55 million | $18.96 million |
| Net loss | $11.80 million | $18.37 million |
| Net loss per share, basic and diluted | $1.76 | $8.21 |
| Cash used in operating activities | $9.86 million | $10.77 million |
| Cash and cash equivalents, year-end | $14.18 million | $7.99 million |
| Working capital, year-end | $12.93 million | $8.11 million |
Margins are not meaningful because the company had no product revenue. Total assets were $24.11 million and total liabilities were $3.98 million at year-end. The filing reports no credit facilities or committed external funding; liabilities included $2.12 million of deferred income taxes and $0.25 million of operating lease liabilities, not material conventional borrowings disclosed in the supplied text.
Financing activities provided $16.04 million in 2019, including $12.32 million from securities offerings and $3.89 million from warrant exercises. The company reported 33.48 million common shares outstanding at December 31, 2019, versus 3.38 million a year earlier, and 22.39 million warrants outstanding at year-end. The reported 2019 loss improved from 2018, substantially because 2018 included a $6.93 million non-cash goodwill impairment and $8.17 million deemed dividend affecting loss attributable to common stockholders; R&D spending increased in 2019.
Programs, outlook, risks and unusual items
- Stroke: PHAST-TSC is a randomized, double-blind Phase 2 study planned for 160 patients, testing ambulance administration for suspected ischemic or hemorrhagic stroke. Enrollment and dosing began in Q4 2019, but the company reported enrollment difficulties. It expected enrollment completion in the second half of 2021, subject to funding; elsewhere it said trial results were not anticipated until 2024.
- GBM: The INTACT Phase 3 trial is designed for 236 newly diagnosed inoperable patients. Its 2019 safety-monitoring review recommended continuation at the tested 1.5 mg/kg dose and reported no adverse safety signal. The company described a preliminary efficacy signal, but the small safety run-in is not definitive efficacy evidence. Randomized enrollment depends on obtaining a strategic partner with sufficient resources.
- Cash runway and going concern: Management stated in several sections that year-end cash was expected to fund operations into January 2021, while another business-section passage said resources would last into Q4 2020. The filing and auditor both identify substantial doubt about the company’s ability to continue as a going concern; additional financing is necessary and not assured. The statements use the going-concern basis and contain no adjustments for a possible failure to continue.
- Financing and dilution: The 2019 equity and warrant financings materially increased shares outstanding and may cause further dilution. The company may need additional equity, debt, licensing or partnership funding and could have to delay programs or grant rights on unfavorable terms.
- Listing: Nasdaq notified the company in December 2019 that its share price had been below $1 for 30 consecutive business days, giving it until June 8, 2020 to regain compliance. Nasdaq also issued a public reprimand relating to the November 2019 offering’s shareholder-approval requirements; it did not delist the shares. A reverse split was under consideration.
- Other risks and contingencies: Development, regulatory approval, trial enrollment, third-party manufacturing, intellectual property, competition and reimbursement are significant uncertainties. A former-CEO-related arbitration was scheduled for November 2020; management said it could not estimate a possible loss and that the matter could materially affect financial position. RES-529’s $8.64 million in-process R&D asset had no impairment recorded in 2019, but management warned its value could be substantially reduced or eliminated.
- Audit and controls: KPMG issued an unqualified opinion on the financial statements and included a going-concern emphasis. Management concluded internal control over financial reporting and disclosure controls were effective; the auditor did not attest to internal-control effectiveness.
Most important facts for investors to verify
- Confirm the issuer identity: the supplied filing is Diffusion Pharmaceuticals Inc., not Cervomed Inc.
- Reconcile the filing’s differing cash-runway statements (Q4 2020 versus January 2021) and assess current financing needs and available cash.
- Check subsequent financing, warrant exercises, share count and potential dilution, including the large year-end warrant overhang.
- Verify PHAST-TSC enrollment progress, timing, funding and any updated results; distinguish preliminary observations from controlled trial evidence.
- Determine whether a strategic partner and funding were secured to start randomized INTACT enrollment, and review any new trial or regulatory updates.
- Review Nasdaq bid-price compliance status and developments in the former executive’s arbitration.